Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WEE1 | P30291 | 17/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.64 |
| ▸ | CCNK | O75909 | 1/20 | 0.46 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
| ▸ | CCND3 | P30281 | 1/20 | 0.46 |
| ▸ | CDK9 | P50750 | 1/20 | 0.46 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17536949 | 0.94 | WEE1 (0.67) | WEE1KCNH2CCNKCCNA2CDK2 | |
| SCHEMBL17536986 | 0.93 | WEE1 (0.70) | WEE1KCNH2CCNKCCNA2CDK2 | |
| SCHEMBL17536951 | 0.92 | KCNH2 (0.73) | WEE1KCNH2CCNKCCNA2CDK2 | |
| SCHEMBL17536965 | 0.91 | WEE1 (0.78) | WEE1KCNH2 | |
| SCHEMBL17536979 | 0.90 | WEE1 (0.67) | WEE1KCNH2 | |
| SCHEMBL17536981 | 0.90 | WEE1 (0.62) | WEE1KCNH2 | |
| SCHEMBL17536947 | 0.89 | WEE1 (0.79) | WEE1KCNH2CCNKCCNA2CDK2 | |
| SCHEMBL17536998 | 0.85 | KCNH2 (0.62) | WEE1KCNH2CCNKCCNA2CDK2 | |
| SCHEMBL16176042 | 0.84 | WEE1 (0.83) | WEE1KCNH2 | |
| SCHEMBL17536972 | 0.84 | WEE1 (0.71) | WEE1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9714244-B2 | Substituted pyrido[4,3-d]pyrimidines as Wee-1 inhibitors | ALMAC DISCOVERY LIMITED (GB) | 2017-07-25 | — | — | US | disclosed |
| EP-2984090-B1 | 2-AMINOPYRIDO[4,3-D]PYRIMIDIN-5-ONE DERIVATIVES AND THEIR USE AS WEE-1 INHIBITORS | ALMAC DISCOVERY LTD (GB) | 2017-05-31 | — | — | EP | disclosed |
| US-20160060258-A1 | 2-AMINOPYRIDO[4,3-D]PYRIMIDIN-5-ONE DERIVATIVES AND THEIR USE AS WEE-1 INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2016-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160060258-A1 | 2-AMINOPYRIDO[4,3-D]PYRIMIDIN-5-ONE DERIVATIVES AND THEIR USE AS WEE-1 INHIBITORS | WEE1, WEE2, NME1 | WEE1 1/4885KCNH2 3746/4885CCNK 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.